ATE292677T1 - Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe - Google Patents

Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe

Info

Publication number
ATE292677T1
ATE292677T1 AT00964563T AT00964563T ATE292677T1 AT E292677 T1 ATE292677 T1 AT E292677T1 AT 00964563 T AT00964563 T AT 00964563T AT 00964563 T AT00964563 T AT 00964563T AT E292677 T1 ATE292677 T1 AT E292677T1
Authority
AT
Austria
Prior art keywords
methods
compositions
dna
agents
damageing
Prior art date
Application number
AT00964563T
Other languages
English (en)
Inventor
Masashi Suganuma
Takumi Kawabe
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP26939899A external-priority patent/JP2001086991A/ja
Priority claimed from JP34032299A external-priority patent/JP2001157585A/ja
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Application granted granted Critical
Publication of ATE292677T1 publication Critical patent/ATE292677T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT00964563T 1999-09-22 2000-09-21 Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe ATE292677T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26939899A JP2001086991A (ja) 1999-09-22 1999-09-22 オリゴペプチド
JP34032299A JP2001157585A (ja) 1999-11-30 1999-11-30 抗癌療法の増強剤とそのスクリーニング方法
PCT/IB2000/001438 WO2001021771A2 (en) 1999-09-22 2000-09-21 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents

Publications (1)

Publication Number Publication Date
ATE292677T1 true ATE292677T1 (de) 2005-04-15

Family

ID=26548750

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964563T ATE292677T1 (de) 1999-09-22 2000-09-21 Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe

Country Status (11)

Country Link
US (2) US6881575B1 (de)
EP (1) EP1218494B1 (de)
JP (1) JP4610828B2 (de)
AT (1) ATE292677T1 (de)
AU (1) AU7548500A (de)
CA (1) CA2385257A1 (de)
DE (1) DE60019318T2 (de)
DK (1) DK1218494T3 (de)
ES (1) ES2239037T3 (de)
PT (1) PT1218494E (de)
WO (1) WO2001021771A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295540C (zh) * 2001-12-17 2007-01-17 奥林巴斯株式会社 显微镜系统
KR100863090B1 (ko) * 2002-01-17 2008-10-13 다케다 파머수티컬 컴패니 리미티드 항증식 활성을 지니고／지니거나 핵산 손상제 또는 처리제를 증강시키는 펩티드 및 펩티드모방체
DE60327804D1 (de) 2002-01-18 2009-07-09 Novozymes As Alanin-2,3-aminomutase
AU2003247044B8 (en) 2002-06-06 2009-04-09 Canbas Co. Ltd. Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA-damaging treatments
JP3990718B2 (ja) 2003-01-09 2007-10-17 ファイザー・インク キナーゼ阻害剤としてのジアゼピノインドール誘導体
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
US7132440B2 (en) 2003-04-17 2006-11-07 Janssen Pharmaceutica, N.V. Substituted benzimidazoles and imidazo-[4,5]-pyridines
WO2004106924A2 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab Testing cell cycle regulation effect of a compound using a hollow fibre cell implant
US7479484B2 (en) 2003-06-25 2009-01-20 Takeda Pharmaceutical Company Limited Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
WO2005014856A1 (en) * 2003-08-08 2005-02-17 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
AU2004274013A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation
ES2362102T3 (es) 2004-06-30 2011-06-28 Janssen Pharmaceutica Nv Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer.
CN101720323A (zh) 2007-04-11 2010-06-02 三井有限公司 具有抗癌活性的化合物
CA2686848A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
AR071774A1 (es) * 2008-05-14 2010-07-14 Takeda Pharmaceutical Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso.
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
MX2018010174A (es) * 2016-02-23 2019-01-10 Takeda Pharmaceuticals Co INHIBIDORES DE INTERACCIONES DE RECEPTOR DE ß-ARRESTINA-NEUROCININ A 1 PARA EL TRATAMIENTO DEL DOLOR.
CN114470178A (zh) * 2019-12-05 2022-05-13 王连生 一种促进心肌再生的重组人chk1蛋白激酶水凝胶及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
WO1998030680A2 (en) * 1997-01-13 1998-07-16 Pharmacia & Upjohn Company Special catalytic domains of cdc25c phosphatase

Also Published As

Publication number Publication date
CA2385257A1 (en) 2001-03-29
DE60019318T2 (de) 2006-03-09
US7851592B2 (en) 2010-12-14
EP1218494B1 (de) 2005-04-06
JP4610828B2 (ja) 2011-01-12
WO2001021771A3 (en) 2002-02-14
US6881575B1 (en) 2005-04-19
AU7548500A (en) 2001-04-24
EP1218494A2 (de) 2002-07-03
DK1218494T3 (da) 2005-08-08
DE60019318D1 (de) 2005-05-12
ES2239037T3 (es) 2005-09-16
JP2003518368A (ja) 2003-06-10
US20050059116A1 (en) 2005-03-17
PT1218494E (pt) 2005-08-31
WO2001021771A2 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
ATE292677T1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
HRP20070189A2 (en) Use of erythropoietin
CY1111590T1 (el) Αρυλ και ετεροαρυλ ουριας αναστολεις chk1 για χρηση ως ραδιοευαισθοποιητες και χημειοευαισθητοποιητες
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
BRPI0409367A (pt) derivados de piperidina inibidores de renina
BRPI0616630B8 (pt) compostos de pirazol substituídos
TW200607513A (en) Certain chemical entities, compositions, and methods
TW200801008A (en) Protein kinase inhibitors
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE473728T1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
TW200722090A (en) Compounds useful for inhibiting chk1
WO2001042784A3 (en) Methods for screening compounds active on neurons
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
BRPI0415355A (pt) triarilimidazóis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1218494

Country of ref document: EP